Vice president and global head of immunology clinical development at AbbVie. Wallace holds an MD and PhD in immunology from the University of Virginia, attended UCLA for pediatric residency and conducted postdoctoral research at the Cedars Sinai IBD Research Institute. She has published in journals such as JAMA, NEJM and The Lancet.
AbbVie’s head of immunology clinical development, Kori Wallace, MD, PhD, discusses how combination therapies, translational science, and emerging immune-reset approaches could usher in a new era of treatment for inflammatory bowel disease and other autoimmune conditions.